$FATE

FATE THERAPEUTICS INC

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for patients with autoimmune diseases and cancer. Its iPSC product platform engineers induced pluripotent stem cells and uses clonal master cell lines to produce T-cell and natural killer cell therapy candidates. The pipeline includes CAR T-cell candidates FT819, FT825, FT836 and FT839, and the CAR NK-cell candidate FT522. These products are designed for clinical investigation, including in autoimmune diseases and solid tumors. Fate also collaborates with Ono Pharmaceutical to research and develop iPSC-derived CAR T-cell and CAR NK-cell candidates for solid tumors. Fate operates a 40,000+ square foot Good Manufacturing Practice facility for manufacturing its iPSC-derived candidates. It seeks to develop its candidates for therapeutic use and to form partnerships for research, development and commercialization of iPSC-derived cell therapies. Fate Therapeutics is headquartered in San Diego, California.

0
0
1
—
$14K
Adawi Kamal
0%
See all $FATE insider activity →

FATE THERAPEUTICS INC (FATE): Entry into a Material Definitive Agreement

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), with respect to an at-the-market offering program (the “ATM Pr

FATE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning FATE (FATE THERAPEUTICS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent FATE coverage spans financial news, earnings and technology.

In the last 30 days, FATE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($14K). The most active reporter was Adawi Kamal, Chief Financial Officer, with 1 filing.

What's driving FATE

AlphAI scores every news story that mentions FATE with an AI model for sentiment and relevance, and aggregates insider trades from FATE THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FATE

Score
$FATEHighOffering· $100M · definitive

FATE THERAPEUTICS INC (FATE): Entry into a Material Definitive Agreement

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), with respect to an at-the-market offering program (the “ATM Pr

Fate Therapeutics 3Q 2026: Revenue $0, EPS ($0.25) — 10-Q Summary

Fate Therapeutics reported no revenue in 3Q 2026, down from $1.74M a year earlier, due to completed performance obligations under its Ono agreement. Net loss narrowed to $30.69M from $32.25M, with lower R&D and G&A expenses. The company initiated a Phase 2 trial for FT819 and expects $139.1M in cash to fund operations for at least 12 months.

$FATEHighEarnings

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa

Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics.

Fate Therapeutics (FATE) appointed Jamie Harrell as commercial leader. Harrell has 25 years of experience in launching autoimmune therapies, including three that topped $1B in U.S. sales. He will lead commercial strategy for FT819, in Phase 2 trials for lupus nephritis, and FT839, in Phase 1/2 trials for multiple autoimmune indications. Harrell previously worked at Aurinia Pharmaceuticals and Avalo Therapeutics.

$FATEMedContract· $15M

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

Related tickers